We are live on ! Find out more
PBA

Paradigm Biocapital Advisors Portfolio holdings

AUM $4.89B
1-Year Est. Return 251.12%
This Fund
S&P 500
This Quarter Est. Return
-9.38%
1 Year Est. Return
+251.12%
3 Year Est. Return
+670.11%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$378M
AUM Growth
+$28M
Cap. Flow
+$68.7M
Cap. Flow %
18.16%
Top 10 Hldgs %
65.17%
Holding
31
New
7
Increased
16
Reduced
2
Closed
6

Top Buys

Rank Stock Value
1
LEGN icon
Legend Biotech
LEGN
+$17.6M
2
INCY icon
Incyte
INCY
+$17.1M
3
ARVN icon
Arvinas
ARVN
+$15.2M
4
UTHR icon
United Therapeutics
UTHR
+$14.4M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$13.3M

Top Sells

Rank Stock Value
1
ARNA
Arena Pharmaceuticals Inc
ARNA
+$23.4M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$16.5M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$15.6M
4
ARGX icon
argenx
ARGX
+$14.7M
5
INSM icon
Insmed
INSM
+$10.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARGX icon
26
argenx
ARGX
$54.1B
– –
-42,050
Closed -$14.7M
ENTA icon
27
Enanta Pharmaceuticals
ENTA
$388M
– –
-75,507
Closed -$5.65M
LKFT
28
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.72B
– –
-167,824
Closed -$9.25M
INSM icon
29
Insmed
INSM
$21.8B
– –
-394,358
Closed -$10.7M
SGEN
30
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-100,687
Closed -$15.6M
ARNA
31
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-251,777
Closed -$23.4M
1
2

Similar funds

KCM
Kensico Capital Management Greenwich, Connecticut $4.9B AUM 41.26% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
FC
Freemont Capital Singapore $4.91B AUM 5.45% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return
MCCA
Mill Creek Capital Advisors Conshohocken, Pennsylvania $4.87B AUM 17.69% 1-Year Est. Return
SIA
Sit Investment Associates Minneapolis, Minnesota $4.93B AUM 12.22% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SMFG
Sumitomo Mitsui Financial Group Tokyo, Japan $4.94B AUM 1.39% 1-Year Est. Return

Paradigm Biocapital Advisors's Q1 2022 Portfolio in Review

As of Q1 2022, Paradigm Biocapital Advisors held 31 positions worth $378M, up 8% from $350M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Paradigm Biocapital Advisors deployed $68.7M of net new capital in Q1 2022, opening 7 new positions and adding to 16 existing holdings. Its largest new stake was Incyte: 234,419 shares worth $18.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Mirati Therapeutics, Inc. Common Stock, an estimated $16.5M trimmed.

  • Paradigm Biocapital Advisors's largest Q1 2022 buy was Incyte: 234,419 shares worth $18.6M.
  • Paradigm Biocapital Advisors added most to Legend Biotech in Q1 2022, an estimated $17.6M increase.
  • Paradigm Biocapital Advisors's biggest Q1 2022 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $16.5M.
  • Paradigm Biocapital Advisors fully exited Arena Pharmaceuticals Inc in Q1 2022, selling an estimated $23.4M.
  • Paradigm Biocapital Advisors's ten largest holdings make up 65% of its $378M portfolio in Q1 2022.
  • Paradigm Biocapital Advisors opened 7 new positions and closed 6 in Q1 2022.
  • Paradigm Biocapital Advisors's portfolio value rose 8% quarter-over-quarter to $378M.

Based on Paradigm Biocapital Advisors's 13F filing for Q1 2022, filed 16 May 2022.